

Listing of the claims

In the Claims

The following Listing of Claims, in which deleted text appears ~~struck through~~ or in double brackets, *e.g.*, [[error]], and inserted text appears underlined, will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 – 58 (canceled).

59 (currently amended). The method of claim ~~58~~ 69, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than about 5 mg/kg/day.

60 (currently amended). The method of claim ~~58~~ 69, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than 200 mg/day.

61 (currently amended). The method of claim ~~58~~ 69, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered for at least 12 weeks.

62 (currently amended). The method of claim ~~58~~ 69, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered once daily.

63 (currently amended). The method of claim ~~58~~ 69, wherein safinamide is administered as the methanesulfonate salt.

64 (currently amended). The method of claim ~~58~~ 69, wherein ~~L-Dopa~~ levodopa is administered with a peripheral decarboxylase inhibitor selected from carbidopa and benserazide.

65 (currently amended). The method of claim ~~58~~ 69, further comprising administering a catechol-O-methyltransferase inhibitor.

66 (previously presented). The method of claim 65, wherein said catechol-O-methyltransferase inhibitor is tolcapone or entacapone.

67 - 68 (canceled).

69 (new). In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of levodopa, the improvement comprising:
concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day,
without reducing the patient's dose of concurrently administered levodopa.

70 (new - withdrawn). In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of dopamine agonist, the improvement comprising:
concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day,
without reducing the patient's dose of concurrently administered dopamine agonist.